Post-Stroke immunodeficiency: Effects of sensitization and tolerization to brain antigens

International Reviews of Immunology

Volumn 31, Issue 5, 2012, Pages 396-409

  Esmaeili, Arash ^a,b   Dadkhahfar, Sahar ^a,b   Fadakar, Kaveh ^a,b   Rezaei, Nima ^b,c,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Immunodeficiency; Stroke; Systemic inflammatory response syndrome; Tolerization

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BRAIN INFECTION; BRAIN ISCHEMIA; CELL DIFFERENTIATION; CEREBROVASCULAR ACCIDENT; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE CELL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE; TH1 CELL;

ADAPTIVE IMMUNITY; AUTOANTIGENS; BACTERIAL INFECTIONS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN ISCHEMIA; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; IMMUNOLOGIC DEFICIENCY SYNDROMES; SIGNAL TRANSDUCTION; STROKE;

EID: 84867829523     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.723078     Document Type: Review

References (111)

1. Macrez R, Ali C, Toutirais O, et al. Stroke and the immune system: From pathophysiology to new therapeutic strategies. Lancet Neurol. 2011;10:471-480.
2. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: Therapeutic approaches. J TranslMed. 2009;7:97.
3. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev. 2000;52:595-638.
4. Cuenca-LopezMD, Brea D,GalindoMF, et al. Inflammatory response during ischaemicprocesses: Adhesion molecules and immunomodulation. Rev Neurol. 2010;51:30-40.
5. Prass K, Dirnagl U. Glutamate antagonists in therapy of stroke. Restor Neurol Neurosci. 1998;13:3-10.
6. Brea D, Sobrino T, Ramos-Cabrer P, Castillo J. Inflammatory and neuroimmunomodulatory changes in acute cerebral ischemia. Cerebrovasc Dis. 2009;27(Suppl 1):48-64.
7. Tuttolomondo A, Di Raimondo D, di Sciacca R, et al. Inflammatory cytokines in acute ischemic stroke. Curr PharmDes. 2008;14:3574-3589.
8. Gourin CG, Shackford SR. Production of tumor necrosis factor-alpha and interleukin-1beta by human cerebralmicrovascular endothelium after percussive trauma. J Trauma. 1997;42:1101-1107.
9. Ahmad M, Graham SH. Inflammation after stroke: Mechanisms and therapeutic approaches. Transl Stroke Res. 2010;1:74-84.
10. del Zoppo GJ.The neurovascular unit, matrix proteases, and innate inflammation. Ann N Y Acad Sci. 2010;1207:46-49.
11. Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 2006;66:232-245.
12. Kriz J. Inflammation in ischemic brain injury: Timing is important. Crit Rev Neurobiol. 2006;18:145-157.
13. McCombe PA, Read SJ. Immune and inflammatory responses to stroke: good or bad? Int J Stroke. 2008;3:254-265.
14. Meisel C, Schwab JM, Prass K, et al. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci. 2005;6:775-786.
15. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184:53-68.
16. Goehler LE, Gaykema RP, Hansen MK, et al. Vagal immune-to-brain communication: A visceral chemosensory pathway. Auton Neurosci. 2000;85:49-59.
17. BanksWA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier.Neuroimmunomodulation. 1995;2:241-248.
18. Banks WA. Blood-brain barrier transport of cytokines: A mechanism for neuropathology. Curr PharmDes. 2005;11:973-984.
19. Buller KM. Role of circumventricular organs in pro-inflammatory cytokine-induced activation of the hypothalamic-pituitary-adrenal axis. Clin Exp Pharmacol Physiol. 2001;28:581-589.
20. Fortier C. Various frontiers in neuroendocrinology. UnionMed Can. 1972;101:2067-2071.
21. Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J Leukoc Biol. 2006;79:1093-1104.
22. Sanders VM, Baker RA, Ramer-Quinn DS, et al. Differential expression of the beta2-adrenergic receptor by Th1 andTh2 clones: Implications for cytokine production and B cell help. J Immunol. 1997;158:4200-4210.
23. Borger P, Hoekstra Y, Esselink MT, et al. Beta-adrenoceptor-mediated inhibition of IFN-gamma,IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. AmJ Respir CellMol Biol. 1998;19:400-407.
24. Felten DL. Neural influence on immune responses: Underlying suppositions and basic principles of neural-immune signaling. Prog Brain Res. 2000;122:381-389.
25. Maestroni GJ. Adrenergic regulation of haematopoiesis. Pharmacol Res. 1995;32:249-253.
26. Chamorro A, Urra X, Planas AM. Infection after acute ischemic stroke: A manifestation of braininduced immunodepression. Stroke. 2007;38:1097-1103.
27. Tang Y, Shankar R, Gamelli R, Jones S. Dynamic norepinephrine alterations in bonemarrow: Evidence of functional innervation. J Neuroimmunol. 1999;96:182-189.
28. Prass K,Meisel C,Hoflich C, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J ExpMed. 2003;198:725-736.
29. Woiciechowsky C, Asadullah K, Nestler D, et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med. 1998;4:808-813.
30. Chamorro A, Amaro S, Vargas M, et al. Catecholamines, infection, and death in acute ischemic stroke. J Neurol Sci. 2007;252:29-35.
31. Klehmet J, Harms H, Richter M, et al. Stroke-induced immunodepression and post-stroke infections: Lessons from the preventive antibacterial therapy in stroke trial. Neuroscience. 2009;158:1184-1193.
32. Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: A role for the hypothalamic-pituitary- adrenal revolving axis. J Neuroimmunol. 2002;133:1-19.
33. Chrousos GP.The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl JMed. 1995;332:1351-1362.
34. Szczudlik A,Dziedzic T, Bartus S, et al. Seruminterleukin-6 predicts cortisol release in acute stroke patients. J Endocrinol Invest. 2004;27:37-41.
35. Woiciechowsky C, Schoning B, Cobanov J, et al. Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. J Trauma. 2002;52:339-345.
36. Wilckens T,De Rijk R. Glucocorticoids and immune function: Unknown dimensions and new frontiers. Immunol Today. 1997;18:418-424.
37. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-andTh2-inducing cytokines. J ExpMed. 2002;195:603-616.
38. Smets LA, Salomons G, van den Berg J. Glucocorticoid induced apoptosis in leukemia. Adv Exp Med Biol. 1999;457:607-614.
39. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol. 1996;156:4422-4428.
40. Franchimont D, Galon J, Gadina M, et al. Inhibition ofTh1 immune response by glucocorticoids: Dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol. 2000;164:1768-1774.
41. Ramirez F, Fowell DJ, Puklavec M, et al. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J Immunol. 1996;156:2406-2412.
42. Marklund N, Peltonen M, Nilsson TK, Olsson T. Low and high circulating cortisol levels predict mortality and cognitive dysfunction early after stroke. J InternMed. 2004;256:15-21.
43. Sawchenko PE, Brown ER, Chan RK, et al. The paraventricular nucleus of the hypothalamus and the functional neuroanatomy of visceromotor responses to stress. Prog Brain Res. 1996;107:201-222.
44. Pavlov VA, Wang H, Czura CJ, et al. The cholinergic anti-inflammatory pathway: A missing link in neuroimmunomodulation.MolMed. 2003;9:125-134.
45. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458-462.
46. Czlonkowska A, Cyrta B, Korlak J. Immunological observations on patients with acute cerebral vascular disease. J Neurol Sci. 1979;43:455-464.
47. Cruse JM, Lewis RE, Bishop GR, et al. Neuroendocrine-immune interactions associated with loss and restoration of immune system function in spinal cord injury and stroke patients. Immunol Res. 1992;11:104-116.
48. Chamorro A,Amaro S, VargasM, et al. Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatry. 2006;77:1279-1281.
49. Offner H, Subramanian S, Parker SM, et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol. 2006;176: 6523-6531.
50. Huschak G, Zur Nieden K, Stuttmann R, Riemann D. Changes in monocytic expression of aminopeptidase N/CD13 aftermajor trauma. Clin Exp Immunol. 2003;134:491-496.
51. Hug A, Dalpke A,Wieczorek N, et al. Infarct volume is amajor determiner of post-stroke immune cell function and susceptibility to infection. Stroke. 2009;40:3226-3232.
52. Harms H, Prass K,Meisel C, et al. Preventive antibacterial therapy in acute ischemic stroke: A randomized controlled trial. Plos One. 2008;3:e2158.
53. Wolk K,DockeWD, von Baehr V, et al. Impaired antigen presentation by humanmonocytes during endotoxin tolerance. Blood. 2000;96:218-223.
54. Vernino S, Brown RD, Jr., Sejvar JJ, et al. Cause-specific mortality after first cerebral infarction: A population-based study. Stroke. 2003;34:1828-1832.
55. Dirnagl U, Klehmet J, Braun JS, et al. Stroke-induced immunodepression: Experimental evidence and clinical relevance. Stroke. 2007;38:770-773.
56. Stott DJ, Falconer A,Miller H, et al. Urinary tract infection after stroke. QJM. 2009;102:243-249.
57. Vermeij FH, Scholte op ReimerWJ, deMan P, et al. Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: Data from the Netherlands Stroke Survey. Cerebrovasc Dis. 2009;27:465-471.
58. Perry L, Love CP. Screening for dysphagia and aspiration in acute stroke: A systematic review. Dysphagia. 2001;16:7-18.
59. Prass K, Braun JS,Dirnagl U, et al. Stroke propagates bacterial aspiration to pneumonia in amodel of cerebral ischemia. Stroke. 2006;37:2607-2612.
60. Jauch EC, Lindsell C, Broderick J, et al. Association of serial biochemical markers with acute ischemic stroke: The National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke. 2006;37:2508-2513.
61. van Zwam M, Huizinga R, Melief MJ, et al. Brain antigens in functionally distinct antigenpresenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med (Berl). 2009;87:273-286.
62. Jander S, Kraemer M, Schroeter M, et al. Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. J Cereb Blood Flow Metab. 1995;15:42-51.
63. Campanella M, Sciorati C, Tarozzo G, BeltramoM. Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke. 2002;33:586-592.
64. WangWZ, Olsson T, Kostulas V, et al.Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol. 1992;88:157-162.
65. Youngchaiyud U, Coates AS,WhittinghamS,Mackay IR. Cellular-immune response tomyelin protein: Absence in multiple sclerosis and presence in cerebrovascular accidents. Aust N Z J Med. 1974;4:535-538.
66. BornsteinNM, Aronovich B, Korczyn AD, et al. Antibodies to brain antigens following stroke.Neurology. 2001;56:529-530.
67. Dambinova SA, Khounteev GA, Izykenova GA, et al. Blood test detecting autoantibodies to Nmethyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003;49:1752-1762.
68. Skvortsova VI, Sherstnev VV, Konstantinova NA, et al. Involvement of autoimmune mechanisms in development of ischemic brain damage. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105: 36-40.
69. Skvortsova VI, Konstantinova EV, Komarov AN, et al. Crioglobulinemia in cerebral and coronal atherothrombosis. Zh Nevrol Psikhiatr ImS S Korsakova. 2005;Suppl 15:51-56.
70. Becker KJ, Kindrick DL, Lester MP, et al. Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood FlowMetab. 2005;25:1634-1644.
71. Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol. 1997;17:89-118.
72. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988;239:290-292.
73. Bechmann I, Peter S, Beyer M, et al. Presence of B7-2 (CD86) and lack of B7-1 (CD(80) onmyelin phagocytosingMHC-II-positive rat microglia is associated with nondestructive immunity in vivo. FASEB J. 2001;15:1086-1088.
74. Suter T, Biollaz G, Gatto D, et al. The brain as an immune privileged site: Dendritic cells of the central nervous system inhibit T cell activation. Eur J Immunol. 2003;33:2998-3006.
75. Chang RC, Chen W, Hudson P, et al. Neurons reduce glial responses to lipopolysaccharide (LPS) and prevent injury of microglial cells from over-activation by LPS. J Neurochem. 2001;76:1042-1049.
76. Adelson JD, Barreto GE, Xu L, et al. Neuroprotection from stroke in the absence ofMHCI or PirB. Neuron. 2012;73:1100-1107.
77. Zierath D, Thullbery M, Hadwin J, et al. CNS immune responses following experimental stroke. Neurocrit Care. 2010;12:274-284.
78. Kendall GS, Hirstova M, Horn S, et al. TNF gene cluster deletion abolishes lipopolysaccharidemediated sensitization of the neonatal brain to hypoxic ischemic insult. Lab Invest. 2011;91:328-341.
79. Becker KJ. Sensitization and tolerization to brain antigens in stroke. Neuroscience. 2009;158:1090-1097.
80. Carty M, Bowie AG. Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem Pharmacol. 2011;81:825-837.
81. Pasare C, Medzhitov R. Toll-like receptors and acquired immunity. Semin Immunol. 2004;16:23-26.
82. HedayatM,NeteaMG,Rezaei N.Targeting ofToll-like receptors: A decade of progress incombating infectious diseases. Lancet Infect Dis. 2011;11:702-712.
83. Hedayat M, Takeda K, Rezaei N. Prophylactic and therapeutic implications of toll-like receptor ligands.Med Res Rev. 2012;32(2):294-325.
84. Rezaei N. Therapeutic targeting of pattern-recognition receptors. Int Immunopharmacol. 2006;6:863-869.
85. Bijani FM, Vallejo JG, Rezaei N. Toll-like receptor signaling pathways in cardiovascular diseases: Hallenges and opportunities. Int Rev Immunol. 2012.
86. HuangYH,HaegerstrandA, Frostegard J. Effects of in vitrohyperthermia on proliferative responses and lymphocyte activity. Clin Exp Immunol. 1996;103:61-66.
87. Jiang-Shieh YF, Yeh KY,Wei IH, et al. Responses ofmicroglia in vitro to the gram-positive bacterial component, lipoteichoic acid. J Neurosci Res. 2005;82:515-524.
88. Lee SJ, Lee S. Toll-like receptors and inflammation in the CNS. Curr Drug Targets Inflamm Allergy. 2002;1:181-191.
89. Zanin-Zhorov A, Tal-Lapidot G, Cahalon L, et al. Cutting edge: T cells respond to lipopolysaccharide innately via TLR4 signaling. J Immunol. 2007;179:41-44.
90. Manicassamy S, Ravindran R, Deng J, et al. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med. 2009;15:401-409.
91. Hilker R, Poetter C, Findeisen N, et al. Nosocomial pneumonia after acute stroke: Implications for neurological intensive caremedicine. Stroke. 2003;34:975-981.
92. Kwan J,Hand P. Infection after acute stroke is associatedwith poor short-termoutcome. ActaNeurol Scand. 2007;115:331-338.
93. Aslanyan S,Weir CJ,DienerHC, et al. Pneumonia and urinary tract infection after acute ischaemic stroke: A tertiary analysis of the GAIN international trial. Eur J Neurol. 2004;11:49-53.
94. Sansing LH, Harris TH, Welsh FA, et al. Toll-like receptor 4 contributes to poor outcome after intracerebral hemorrhage. Ann Neurol. 2011;70:646-656.
95. Bohacek I, Cordeau P, Lalancette Hebert M, et al. Toll-like receptor 2 deficiency leads to delayed exacerbation of ischemic injury. J Neuroinflammation. 2012;9:191.
96. Hallenbeck J.Howinflammationmodulates central nervous system vessel activation and provides targets for intervention-a personal perspective. Ann N Y Acad Sci. 2010;1207:1-7.
97. Bevilacqua MP, Stengelin S, Gimbrone MA, Jr., Seed B. Endothelial leukocyte adhesion molecule 1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science. 1989;243:1160-1165.
98. Chen Y, Ruetzler C, Pandipati S, et al.Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A. 2003;100:15107-15112.
99. YunW,Qing-Cheng L, Lei Y, Jia-Yin M.Mucosal tolerance to E-selectin provides protection against cerebral ischemia-reperfusion injury in rats. J Neuroimmunol. 2008;205:73-79.
100. Ishibashi S,Maric D,Mou Y, et al.Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J Cereb Blood FlowMetab. 2009;29:606-620.
101. Wakita H, Ruetzler C, Illoh KO, et al. Mucosal tolerization to E-selectin protects against memory dysfunction and white matter damage in a vascular cognitive impairment model. J Cereb Blood FlowMetab. 2008;28:341-353.
102. Weiner HL.Themucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol. 2001;2:671-672.
103. Balabanov R, Beaumont T, Dore-Duffy P. Role of central nervous system microvascular pericytes in activation of antigen-primed splenic T-lymphocytes. J Neurosci Res. 1999;55:578-587.
104. Green EA,Gorelik L,McGregor CM, et al. CD4+CD25+T regulatory cells control anti-islet CD8+T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA. 2003;100:10878-10883.
105. Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J ExpMed. 1991;174:791-798.
106. Wolvers DA, Coenen-de Roo CJ,Mebius RE, et al. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: StudieswithOVA and human cartilage gp-39. J Immunol. 1999;162:1994-1998.
107. Frenkel D, Huang Z, Maron R, et al. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J Immunol. 2003;171:6549-6555.
108. Gee JM, Kalil A,ThullberyM, Becker KJ. Induction of immunologic tolerance tomyelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke. Stroke. 2008;39:1575-1582.
109. Gee JM, Zierath D, Hadwin J, et al. Long termimmunologic consequences of experimental stroke andmucosal tolerance. Exp Transl StrokeMed. 2009;1:3.
110. Takeda H, Spatz M, Ruetzler C, et al. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke. 2002;33:2156-2163.
111. Faria AM,Weiner HL.Oral tolerance: Therapeutic implications for autoimmune diseases. ClinDev Immunol. 2006;13:143-157.